IN THE CLAIMS:

The listing of claims below will replace all prior versions and listings of claims in this application.

Listing Of Claims:

1. (Currently amended) A compound of formula (**I**):



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)- or -SO_2-;

X is H;

Z is (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{1-4}-alkyl)-O-(C_{1-4}-alkyl), (C_{1-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), ~~(C_{0-4}-alkyl)-dichloropyridine,~~ or CH_2NSO_2-(C_{1-4}-alkyl);

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or (C_{1-4}-alkyl)-cycloalkyl;

R^3 is, NR^4 R^5, OH, or O-(C_{1-8}-alkyl);

R^4 is H;

R^5 is -OH, or -O-C(O)R^6;

R^6 is C_{1-8}-alkyl, amino-(C_{1-8}-alkyl), (C_{1-8}-alkyl)-(C_{3-6}-cycloalkyl), C_{3-6}-cycloalkyl, phenyl, benzyl, or aryl;

or a pharmaceutically acceptable salt, ~~or~~ solvate, stereoisomer or clathrate thereof.

2. (Original) The compound of claim 1, wherein Z is (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{1-4}-alkyl)-O(C_{1-4}-alkyl), (C_{1-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), or CH_2NSO_2(C_{1-4}-alkyl).

3-4. (Canceled)

5. (Currently amended) The compound of claim 1 ~~or 3~~ wherein R_1 is CH_3.

6. (Currently amended) The compound of claim 1 ~~or 3~~ wherein R_2 is CH_2CH_3, CH_3, CH_2-cyclopropyl, or cyclopentyl.

7. (Currently amended) The compound of claim 1 ~~or 3~~ wherein Y is –C(O)- or -CH_2-.

8-10. (Canceled)

11. (Currently amended) An enantiomerically pure S isomer of a compound of claim 1~~, 3 or 9~~, substantially free of its R isomer, or a pharmaceutically acceptable salt, solvate, ~~hydrate,~~ stereoisomer, or clathrate~~, or prodrug~~ thereof.

12. (Currently amended) An enantiomerically pure R isomer of a compound of claim 1~~, 3 or 9~~, substantially free of its S isomer, or a pharmaceutically acceptable salt, solvate, ~~hydrate,~~ stereoisomer, or clathrate~~, or prodrug~~ thereof.

13. (Currently amended) A compound, wherein the compound is:
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-hydroxy-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(3R)-(tert-Butoxy)-N-{3-[7-(cyclopropylcarbonylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propyl}carbonylamino (tert-butoxy)formate;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-hydroxyamino-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-methanesulfonylamino-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[3-amino-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-ureido-propyl]-3-oxo-

2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[3-dimethylamino-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide hydrochloride;

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-methanesulfonyl-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)- Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-hydroxycarbamoyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[2-acetoxycarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(3R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-methanesulfinyl-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(3R)-3-[4-Chloro-7-(cyclopropanecarbonyl-amino)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(3-ethoxy-4-methoxy-phenyl)-propionic acid;

(3R)-3-[4-Chloro-7-(cyclopropanecarbonyl-amino)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(3-ethoxy-4-methoxy-phenyl)-propionic acid methyl ester;

(1R)-Cyclopropanecarboxylic acid {2-[2-carbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {7-chloro-2-[2-dimethylcarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {7-chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-hydroxycarbamoyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[2-acetoxycarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1S)-Cyclopropanecarboxylic acid {7-chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1S)-Cyclopropanecarboxylic acid {7-bromo-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

~~Cyclopropanecarboxylic acid {2-[2-(3,5-dichloro-pyridin-4-yl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;~~

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-hydroxy-3-methyl-

butyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[2-cyclopropanecarbonyloxycarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-isobutyryloxycarbamoyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[2-(2,2-dimethyl-propionyloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[2-(3,3-dimethyl-butyryloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1S)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-7-fluoro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1S)-3-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-1,1-dimethyl-urea;

(1S)-N-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-2-(4-methyl-piperazin-1-yl)-acetamide;

(1S)-N-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-2-morpholin-4-yl-acetamide hydrochloride;

(1S)-N-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-2-dimethylamino-acetamide hydrochloride.

14. (Currently amended) A compound of the formula:



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

, or

.

or a pharmaceutically acceptable salt or solvate thereof.

15. (Canceled)

16. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound of formula (I):



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)- or -SO_2-;

X is H;

Z is (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{1-4}-alkyl)-O-(C_{1-4}-alkyl), (C_{1-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), ~~(C_{0-4}-alkyl)-dichloropyridine,~~ or CH_2NSO_2-(C_{1-4}-alkyl);

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or (C_{1-4}-alkyl)-cycloalkyl;

R^3 is, NR^4 R^5, OH, or O-(C_{1-8}-alkyl);

R^4 is H;

R^5 is -OH, or -O-C(O)R^6;

R^6 is C_{1-8}-alkyl, amino-(C_{1-8}-alkyl), (C_{1-8}-alkyl)-(C_{3-6}-cycloalkyl), C_{3-6}-cycloalkyl, phenyl, benzyl, or aryl;

or a pharmaceutically acceptable salt or solvate thereof.

17-21. (Canceled)

22. (New) The compound of claim 1, wherein said solvate is a hydrate.

23. (New) The enantiomerically pure S isomer of claim 11, wherein said solvate is a hydrate.

24. (New) The enantiomerically pure R isomer of claim 12, , wherein said solvate is a hydrate.